Second quarter report Q2-2023
· US co-development and commercialization partnership signed for CT001 - potential income already from 2024 · Strong clinical progress · Pivotal study 0205 recruitment on track - last patient expected Q3-2023 · Clinical Trial Application (CTA) for study 0202 submitted and under review by competent authorities · Post-period event: Loan facility agreement signed to support US launch and strengthening the cash positionCessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 April – 30 June 2023. The second quarter report is available as an